Unknown

Dataset Information

0

Switching to PegIFN?-2b leads to HBsAg loss in patients with low HBsAg levels and HBV DNA suppressed by NAs.

ABSTRACT: Patients with low hepatitis B surface antigen (HBsAg) levels and hepatitis B virus (HBV) DNA suppression by nucleos(t)ide analogues (NAs) achieve high rate of HBsAg loss through switching to PegIFN? in pre-registration study. The aim of this study was to achieve higher rate of HBsAg loss through extended PegIFN treatment. 98 patients with HBsAg?

SUBMITTER: Huang J 

PROVIDER: S-EPMC5645387 | biostudies-literature | 2017 Oct

REPOSITORIES: biostudies-literature

Json Xml
altmetric image

Publications

Switching to PegIFNα-2b leads to HBsAg loss in patients with low HBsAg levels and HBV DNA suppressed by NAs.

Huang Jing J   Zhang Ka K   Chen Wenli W   Liao Jinyao J   Luo Xiaodan X   Chen Ren R  

Scientific reports 20171017 1

Patients with low hepatitis B surface antigen (HBsAg) levels and hepatitis B virus (HBV) DNA suppression by nucleos(t)ide analogues (NAs) achieve high rate of HBsAg loss through switching to PegIFNα in pre-registration study. The aim of this study was to achieve higher rate of HBsAg loss through extended PegIFN treatment. 98 patients with HBsAg < 2,000 IU/ml and HBV DNA < 20 IU/ml were randomized to receive PegIFNα-2b or continuing NA therapy for 60 weeks. At the end of treatment (EOT) and end o  ...[more]

Similar Datasets

Unknown Key mutations in the C-terminus of the HBV surface glycoprotein correlate with lower HBsAg levels <i>in vivo</i>, hinder HBsAg secretion <i>in vitro</i> and reduce HBsAg structural stability in the setting of HBeAg-negative chronic HBV genotype-D infection.
| S-EPMC7269061 | biostudies-literature
Unknown Naturally Occurring Mutations within HBV Surface Promoter II Sequences Affect Transcription Activity, HBsAg and HBV DNA Levels in HBeAg-Positive Chronic Hepatitis B Patients.
| S-EPMC6356792 | biostudies-literature
Unknown Identification and Mapping of HBsAg Loss-Related B-Cell Linear Epitopes in Chronic HBV Patients by Peptide Array.
| S-EPMC8554339 | biostudies-literature
Unknown A Hyper-Glycosylation of HBV Surface Antigen Correlates with HBsAg-Negativity at Immunosuppression-Driven HBV Reactivation in Vivo and Hinders HBsAg Recognition in Vitro.
| S-EPMC7077195 | biostudies-literature
Unknown HBsAg isoform dynamics during NAP-based therapy of HBeAg-negative chronic HBV and HBV/HDV infection.
| S-EPMC9315123 | biostudies-literature
Unknown Prediction Model of HBsAg Seroclearance in Patients with Chronic HBV Infection.
| S-EPMC7443222 | biostudies-literature
Unknown In Situ Liver Expression of HBsAg/CD3-Bispecific Antibodies for HBV Immunotherapy.
| S-EPMC5626922 | biostudies-literature
Unknown Performance evaluation of 70 hepatitis B virus (HBV) surface antigen (HBsAg) assays from around the world by a geographically diverse panel with an array of HBV genotypes and HBsAg subtypes.
| S-EPMC2860763 | biostudies-literature
Unknown IP-10 Expression in Patients with Chronic HBV Infection and Its Ability to Predict the Decrease in HBsAg Levels after Treatment with Entecavir.
| S-EPMC5523018 | biostudies-other
Unknown The cyclophilin inhibitor CRV431 inhibits liver HBV DNA and HBsAg in transgenic mice.
| S-EPMC6557616 | biostudies-literature